Ezaki, Taketo

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy ( Shiba-Kyoritsu )

Position

Research Associate/Assistant Professor/Instructor
Page Top ▲
 

Papers 【 Display / hide 】

  • Development of microsurgical forceps equipped with haptic technology for in situ differentiation of brain tumors during microsurgery

    Ezaki T., Kishima K., Shibao S., Matsunaga T., Pareira E.S., Kitamura Y., Nakayama Y., Tsuda N., Takahara K., Iwama T., Sampetrean O., Toda M., Ohnishi K., Shimono T., Sasaki H.

    Scientific Reports 14 ( 1 )  2024.12

    　View Summary

    The stiffness of human cancers may be correlated with their pathology, and can be used as a biomarker for diagnosis, malignancy prediction, molecular expression, and postoperative complications. Neurosurgeons perform tumor resection based on tactile sensations. However, it takes years of surgical experience to appropriately distinguish brain tumors from surrounding parenchymal tissue. Haptics is a technology related to the touch sensation. Haptic technology can amplify, transmit, record, and reproduce real sensations, and the physical properties (e.g., stiffness) of an object can be quantified. In the present study, glioblastoma (SF126-firefly luciferase-mCherry [FmC], U87-FmC, U251-FmC) and malignant meningioma (IOMM-Lee-FmC, HKBMM-FmC) cell lines were transplanted into nude mice, and the stiffness of tumors and normal brain tissues were measured using our newly developed surgical forceps equipped with haptic technology. We found that all five brain tumor tissues were stiffer than normal brain tissue (p < 0.001), and that brain tumor pathology (three types of glioblastomas, two types of malignant meningioma) was significantly stiffer than normal brain tissue (p < 0.001 for all). Our findings suggest that tissue stiffness may be a useful marker to distinguish brain tumors from surrounding parenchymal tissue during microsurgery, and that haptic forceps may help neurosurgeons to sense minute changes in tissue stiffness.

  • Optimizing perampanel monotherapy for surgically resected brain tumors

    Hino U., Tamura R., Kosugi K., Ezaki T., Karatsu K., Yamamoto K., Tomioka A., Toda M.

    Molecular and Clinical Oncology 20 ( 6 )  2024.06

    ISSN  20499450

    　View Summary

    Perampanel (PER) is an antiseizure medication (ASM) with a unique mechanism of action, which was approved in Japan for use in combination therapy in 2016 and as a monotherapy in 2020. It has exerted antitumor effects against several types of tumors in vitro. However, the efficacy of PER monotherapy for seizure control is not well established in patients with brain tumor. In the present study, 25 patients with brain tumor treated using PER monotherapy at our institution were analyzed and compared with 45 patients treated using the most commonly prescribed ASM, levetiracetam (LEV). The PER group was younger and had a higher frequency of glioma cases. During drug administration, seizures were observed in two patients from the PER group (8.0%) and five patients from the LEV group (11.1%); however, the difference was not significant. The incidence of adverse effects did not significantly differ between the groups (12.0 and 2.2%, respectively). In the PER group, mild liver dysfunction was observed in two patients and drug rash in one. In the LEV group, a drug induced rash was observed in one patient. PER monotherapy may be safe and effective for seizure treatment or prophylaxis in patients with brain tumor. Further large scale clinical studies are warranted.

  • Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment

    Ezaki T., Tanaka T., Tamura R., Ohara K., Yamamoto Y., Takei J., Morimoto Y., Imai R., Kuranai Y., Akasaki Y., Toda M., Murayama Y., Miyake K., Sasaki H.

    Brain Tumor Pathology 41 ( 2 ) 61 - 72 2024.04

    ISSN  14337398

    　View Summary

    Glioblastoma multiforme (GBM) acquires resistance to bevacizumab (Bev) treatment. Bev affects angiogenic factors other than vascular endothelial growth factor (VEGF), which are poorly understood. We investigated changes in angiogenic factors under and after Bev therapy, including angiopoietin-1 (ANGPT1), angiopoietin-2 (ANGPT2), placental growth factor (PLGF), fibroblast growth factor 2, and ephrin A2 (EphA2). Fifty-four GBM tissues, including 28 specimens from 14 cases as paired specimens from the same patient obtained in three settings: initial tumor resection (naïve Bev), tumors resected following Bev therapy (effective Bev), and recurrent tumors after Bev therapy (refractory Bev). Immunohistochemistry assessed their expressions in tumor vessels and its correlation with recurrent MRI patterns. PLGF expression was higher in the effective Bev group than in the naïve Bev group (p = 0.024) and remained high in the refractory Bev group. ANGPT2 and EphA2 expressions were higher in the refractory Bev group than in the naïve Bev group (p = 0.047 and 0.028, respectively). PLGF expression was higher in the refractory Bev group compared with the naïve Bev group for paired specimens (p = 0.036). PLGF was more abundant in T2 diffuse/circumscribe patterns (p = 0.046). This is the first study to evaluate angiogenic factors other than VEGF during effective and refractory Bev therapy in patient-derived specimens.

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • PRIOR LEARNING FOR CLINICAL PRACTICE 4

    2026

  • RESEARCH FOR BACHELOR'S THESIS 1

    2026

  • PRE-CLINICAL TRAINING IN PRESCRIPTION PROCESSING FOR HOSPITAL & COMMUNITY PHARMACY

    2026

  • CLINICAL PHARMACOKINETICS

    2026

  • PHARMACEUTICAL-ENGLISH SEMINAR

    2026

display all >>

Page Top ▲